Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Engineering × Endocrine × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 33 Everolimus 29 Magnetic Resonance Spectroscopy 20 pembrolizumab 17 Temozolomide 16 Nivolumab 14 Cisplatin 14 lenvatinib 13 gallium Ga 68 dotatate 13 cabozantinib 13 3-Iodobenzylguanidine 13 lanreotide 12 Capecitabine 12 trametinib 11 dabrafenib 11 Bevacizumab 11 Surgical Procedures, Operative 10 Octreotide 10 Surveys and Questionnaires 9 Positron Emission Tomography Computed Tomography 9 Paclitaxel 9 Blood Specimen Collection 9 Ipilimumab 8 Carboplatin 8 177Lu-octreotide, DOTA(0)-Tyr(3)- 8 fluorodopa F 18 7 Sunitinib 7 Sorafenib 7 Somatostatin 7 Radiotherapy 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07366658 2026-01-26

NEUK203-13

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1 Not yet recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡